“showed a trend”

PDR blood sample analysis as compared to controls showed a trend for increased expression of VEGFA by 1.2-fold (PDR = 0.88, control = 0.74, p = 0.57), whereas the other examined genes showed a trend of reduced expression; HIF2A decreased by 0.50-fold (PDR = 0.38, control = 0.75, p = 0.07), PAI by 0.51-fold (PDR = 0.35, control = 0.69, p = 0.09), TIE-1 by 0.79-fold (PDR = 0.79, control = 1.00, p = 0.54), TIE-2 by 0.70-fold (PDR = 0.58, control = 0.82, p = 0.34), and ANGPT2 by 0.45-fold (PDR = 0.51, control = 1.15, p = 0.11).

However, BCG responders showed a trend toward increased CD4 + /T reg ratio compared to BCG failure (after three instillations, 1.26 ± 0.85 vs. 0.69 ± 0.12, p = 0.571).

Although diabetes mellitus (DM) showed a trend toward increased hazard (HR = 1.906, 95 % CI: 0.202–17.998, p = 0.574), but lacks statistical significance.

In terms of treatment response, after two months of anti-TB treatment, the extended treatment group showed a trend toward higher rates of persistent positive sputum AFS (16.4% vs. 11.3%, p = 0.58) and positive culture for Mycobacterium tuberculosis (10% vs. 5%, p = 0.274) compared with the standard treatment group.

Although not statistically significant, patients who underwent surgery with CPB showed a trend toward longer intensive care unit stays (8.55 vs 6.04 days; P = .58), longer hospital stays (26.86 vs 16.2 days; P = .12), and a higher rate of perioperative complications (31.8% vs 12.0%; P = .15), compared with those treated without CPB.

The ML model showed a trend toward higher sensitivity (0.74 vs. 0.58, p = 0.58) and NPV (0.98 vs. 0.97, p = 0.59) compared with the non‐ML model, although the differences were not statistically significant.

The results suggested that melatonin intervention had no significant effects on LVEF, LVEDV, and LVESV compared to the control groups but showed a trend to enhance LVEF (SMD: 0.11; 95% CI: −0.29 to 0.52; P = 0.58; and I 2 = 78.4%), LVEDV (SMD: 0.13; 95% CI: −0.08 to 0.34; P = 0.22; and I 2 = 0%), and LVESV (SMD: 0.20; 95% CI: −0.03 to 0.43; P = 0.095; and I 2 = 18.1%) in Figure 3(a) .

Although non-significant, the LPS + PBS group showed a trend toward an elevated rheobase (Fig. 8 A, C; interaction: F (1, 32) = 0.3062, P = 0.5839; LPS: F (1, 32) = 4.444, P = 0.429; LAM: F (1, 32) = 1.790, P = 0.1904).

However, compared to finasteride or conventional treatment, dietary supplements only showed a trend of increased blind doctor evaluation, with no statistically significant difference (RR = 0.56, p = 0.587) (see Supplementary Figure S18 ).

Patients operated for a single liver metastasis showed a trend in improved OS, when compared with those with multiple metastases: median OS was 14 versus 22 months, respectively ( p = 0.590 at log-rank test) ( Figure 3(d) ).

In the first cohort, AgeAccel showed a trend toward a correlation with IEAA (rho = 0.566, p = 0.590) and EEAA (rho = 0.629, p = 0.0324).

PICP and the ratio of PICP/ICTP showed a trend towards higher in hypertension patients with uncontrolled BP than well-controlled (76.6 ± 13 ug/L vs. 66.82 ± 15.3 ug/L, p = 0.59 and 73.22 ± 13.6 vs. 66.82 ± 15.3, p = 0.96, respectively), and it was proved that there were correlations between increased ECV and elevated serum fibrosis biomarkers level (PICP: β = 0.37, p = 0.02, PICP/ICTP: β = 0.30, p = 0.03) (Table 2 ).

Intravenous magnesium administered within 12 hours lowered systolic blood pressure by 4 mmHg and showed a trend towards improved outcome in all stroke patients (odds ratio: 0.95, 95% CI 0.80–1.13, P = 0.59).

Although no significant difference in driver genes' amplification was observed between pairs of subclasses, C2 still showed a trend toward higher amplification rate (e.g., FGF19: 9.09%) than C1 (7.07%, P = 0.59) and C3 (4.31%, P = 0.21; detailed statistical analyses are shown in Table S10 ). 3.7 Ninety‐gene classifier and performance validation Differential analysis yielded 509 significant genes for the C1 subclass, 2042 for the C2 subclass, and 279 for the C3 subclass.

In the cohort of 39 patients, EGFR-TKI monotherapy showed a trend toward longer MPE recurrence-free survival compared with the combination group (median 352 days vs. 298 days; P=0.59) ( 15 ).

In EODM, overall GRS and complement GRS showed a trend of increasing GRS and complement GRS, with increasing severity of disease stages ( p = 0.59 and p = 0.17, respectively).

Patients with high USP4 protein levels showed a trend for a prolonged overall survival (13.6 vs. 7.1, p = 0.598) and disease-free survival (not reached-12.7 months, p = 0.999).

Salivary C showed a trend, increasing from pre (7.9±6.2 nmol/L) to 30min post (18.8±12.7 nmol/L -p=0.60-) and 60min post (18.1±14.7 nmol/L -p=0.93-) in PL while no significant changes or trends were observed for MTN (10.1±7.0 Vs 16.6±13.9 and 12.8±8.5 respectively).

In the patellar tendon group, bracing showed a trend toward lower scores (MD = −0.64; 95% CI, −3.00 to 1.72; p = 0.60), but this was not statistically significant (Figure 10 ). 2.

The absolute and relative weight of the spleen showed a trend to be heavier in pigs from the group T at 180 days-old (74.1 ± 2.9 vs. 88.0 ± 4.1 g and 0.98 ± 0.03 vs. 1.1 ± 0.05; p = 0.60).

The MED (mg/kg/day) reported at 1 week preamputation and 1 week and 1, 3, and 6 months postamputation, showed a trend toward higher values at 1 week [median 0.2 (range 0–7.6); p = 0.6) and 3 months [median 0.2 (range 0–0.5); p = 0.3) postsurgery versus presurgery [median 0.1 (range 0–0.5)].

Results: With a median follow up of 21.2 months, CPX-351 showed a trend towards better OS (not reached vs 15.4 months, p = 0.6) and lower disease-related mortality (25.0% vs 83.3%), compared to SOC.

Elderly patients showed a trend towards increased postoperative morbidity after bilobectomy (50% vs. 20% for younger patients, p = 0.6).

The expression of HMGB1 mRNA also showed a trend to increase at 1 month (1.2±0.8) and 3 months (1.3±0.7) after transplantation compared with before transplant (1.1±0.5) (at 1 month P = 0.60; at 3 months, P = 0.36) ( Figure 4B ).

Though not reaching statistical significance, when compared to non-outliers, outliers showed a trend towards older age (78.9±4.1 vs. 75.5±5.5 years, p=0.60), greater severity of cognitive impairment (CDR global scores 1.1±0.7 vs. 0.7±0.4, p=0.82; CDR sum of boxes scores 5.1±3.3 vs. 2.8±2.6, p=0.71), and lower educational levels (7.3±5.9 vs. 8.6±3.8 years, p=0.35).